Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

News: Cancer Research

Discovery Lecture to feature VICC experts

Thursday, May 14th, 2015

Three Vanderbilt University scientists will describe “gene-environment interactions in cancer etiology and prevention” at 4 p.m. Thursday, May 21, in 208 Light Hall. The panel discussion of “cutting-edge discovery” at Vanderbilt is the final Flexner Discovery Lecture of the 2014-2015 academic year. Speakers include: • Robert J. Coffey Jr., M.D., Ingram Professor of Cancer Research, professor […]

VICC research efforts in spotlight at AACR conference

Thursday, April 30th, 2015

Adding an investigational drug to an already approved estrogen blocking therapy appears to be safe and provided clinical benefit for some postmenopausal women with estrogen-positive breast cancer. The research led by Ingrid Mayer, M.D., associate professor of Medicine and clinical director of the Breast Cancer Program at Vanderbilt-Ingram Cancer Center (VICC), was selected for the […]

Best hospital depends on cancer type

Thursday, April 23rd, 2015

The idea of a “Best Hospital for Cancer” does not reflect the fact that cancer comprises many different diseases. Jeffery Goldstein, M.D., Ph.D., a resident in the Department of Pathology, Microbiology and Immunology at Vanderbilt, and Vinay Prasad, M.D., MPH, aimed to rank the 50 highest ranked cancer hospitals – from the 2013 U.S. News […]

Statin use improves renal cell cancer survival

Friday, April 17th, 2015

A new study led by Vanderbilt University investigators found that patients being treated with statins at the time of surgery for kidney cancer, also known as renal cell carcinoma, had improved overall survival and disease-specific survival. Drugs known as statins are widely used to lower cholesterol and previous studies have indicated that they could be […]

Cancer signaling pathway blocker

Friday, April 10th, 2015

Researchers at Vanderbilt University have discovered a new way to inhibit Hedgehog (Hh) signaling, an important regulatory pathway for vertebrate development – and cancer. Abnormal regulation of this pathway leads to several human malignancies, including small cell lung cancer and pancreatic cancer, and therefore it is a potential drug target for cancer. Small molecules have […]

Micelle “packets” deliver cancer drugs

Friday, April 10th, 2015

Small interfering RNA (siRNA) molecules can suppress tumor growth and target cells otherwise untreatable by conventional therapeutics, but targeted, intracellular delivery is a significant limitation to siRNA translation. To deliver the siRNA molecules into tumor cells, researchers have packaged them in micelles that express folic acid, which is internalized by cancer cells that overexpress folate […]

New driver behind lung cancer progression

Thursday, April 2nd, 2015

Vanderbilt-Ingram Cancer Center investigators have identified the mechanisms used by a gene and its binding protein to drive tumor growth in several forms of cancer, including non-small cell lung cancer. In a report published online recently in the Proceedings of the National Academy of Sciences (PNAS), first author Jun Qian, Ph.D., lead investigator Pierre Massion, M.D., […]

‘Docking stations’ on chromosomes new anti-cancer target

Thursday, March 26th, 2015

Vanderbilt University researchers have discovered a cleft in a chromosome-binding protein that may hold the key to stopping most cancers in their tracks. The protein, WDR5, is a “docking station” for a family of transcription factors called MYC that is overexpressed in the majority of malignancies and which contributes to an estimated 100,000 cancer-related deaths […]

VICC’s Johnson to study cancer survivorship with immune inhibitor drugs

Thursday, March 19th, 2015

Douglas Johnson, M.D., assistant professor of Medicine, has been named a recipient of the National Comprehensive Cancer Network  (NCCN) Foundation Young Investigator Awards. The two-year grant will provide $150,000 in funding for his research on survivorship among cancer patients who receive drugs called immune checkpoint inhibitors. The formal announcement of the grant awardees was made […]

Team blends high-end imaging techniques

Monday, March 16th, 2015

Vanderbilt University researchers have achieved the first “image fusion” of mass spectrometry and microscopy — a technical tour de force that could, among other things, dramatically improve the diagnosis and treatment of cancer. Microscopy can yield high-resolution images of tissues, but “it really doesn’t give you molecular information,” said Richard Caprioli, Ph.D., senior author of […]

Next Page »« Previous Page